Updates on management of gliomas in the molecular age

Brandon Lucke Wold

University of Florida , USA

Biography :

Brandon Lucke-Wold, a Colorado Springs native, achieved magna cum laude honors in Neuroscience from Baylor University. He holds an MD/PhD, a Master’s in Clinical and Translational Research, and completed the Global Health Track at West Virginia University School of Medicine. Specializing in traumatic brain injury, neurosurgical simulation, and stroke research, he co-founded SwiftScience and ProPhos Neuroscience. Brandon’s leadership roles at WVU included president of various chapters and active membership in prestigious honor societies. Currently a Pgy6 neurosurgery resident at the University of Florida, he serves in leadership capacities, including Vice President of the UF House Staff Council. Outside medicine, Brandon enjoys family activities, running, rock climbing, and traveling. His commitment to advancing neurosurgery and cerebrovascular research is evident through multiple fellowships.

Abstract :

Gliomas are primary brain tumors derived from glial cells of the central nervous system, afflicting
both adults and children with distinct characteristics and therapeutic challenges. Recent
developments have ushered in novel clinical and molecular prognostic factors, reshaping
treatment paradigms based on classification and grading, determined by histological
attributes and cellular lineage. This review article delves into the diverse treatment modalities
tailored to the specific grades and molecular classifications of gliomas that are currently being
discussed and used clinically in the year 2023. For adults, the therapeutic triad typically
consists of surgical resection, chemotherapy, and radiotherapy. In contrast, pediatric gliomas,
due to their diversity, require a more tailored approach. Although complete tumor excision
can be curative based on the location and grade of the glioma, certain non-resectable cases
demand a chemotherapy approach usually involving, vincristine and carboplatin. Additionally
, if surgery or chemotherapy strategies are unsuccessful, Vinblastine can be used. Despite
recent advancements in treatment methodologies, there remains a need of exploration in the
literature, particularly concerning the efficacy of treatment regimens for isocitrate dehydrogenase
type mutant astrocytomas and fine-tuned therapeutic approaches tailored for pediatric
cohorts. This review article explores into the therapeutic modalities employed for both
adult and pediatric gliomas in the context of their molecular classification.